RecruitingPhase 2NCT06483100
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Studying Post-transplant lymphoproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Washington University School of Medicine
- Principal Investigator
- Michael Slade, M.D.Washington University School of Medicine
- Intervention
- Elrantamab(drug)
- Enrollment
- 65 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2031
Study locations (1)
- Washington University School of Medicine, St Louis, Missouri, United States
Collaborators
National Comprehensive Cancer Network · Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06483100 on ClinicalTrials.govOther trials for Post-transplant lymphoproliferative disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07389616A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGNCT07470996T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NRShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE2NCT06723457Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaNorthwestern University
- RECRUITINGPHASE1, PHASE2NCT07368634Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE2NCT06954805Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)Jennifer Amengual
- RECRUITINGPHASE1, PHASE2NCT07438067EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell TransplantationDaihong Liu
- ACTIVE NOT RECRUITINGNCT06422715PTLD: Multicentric Retrospective StudyFondazione Italiana Linfomi - ETS
- RECRUITINGNCT06698887A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in KoreaBristol-Myers Squibb
See all trials for Post-transplant lymphoproliferative disease →